Inactive Instrument

Recipharm AB (publ)

RECI B

SE0005757267

Recipharm Appoints Vikas Gupta as President of ReciBioPharm

May 03, 2023

Recipharm named Vikas Gupta as President of its recently renamed biologics business arm. Gupta joins ReciBioPharm from Repligen, where he was Vice President & General Manager, Gene Therapy and Downstream Bioprocessing. The appointment comes as Recipharm officially renames its biologics business division after the acquisitions of Arranta Bio, GenIbet and Vibalogics.

Latest news about Recipharm AB (publ)

Blue Wolf Capital Partners LLC agreed to acquire Seven manufacturing and development facilities of Recipharm AB.	Apr. 01	CI
Synokem Pharmaceuticals Limited acquired 74% stake in Nitin Lifesciences Limited from Recipharm AB.	Nov. 27	CI
Recipharm Announces CEO Changes	Nov. 22	CI
Recipharm Appoints Marc Funk as Board of Directors	Nov. 22	CI
Recipharm Announces Executive Appointments	23-08-23	CI
NewBiologix SA announced that it has received CHF 45 million in funding from Recipharm AB and other investors	23-05-10	CI
Recipharm Appoints Vikas Gupta as President of ReciBioPharm	23-05-03	CI
Recipharm Announces Chief Financial Officer Changes	23-04-04	CI
RS BioTherapeutics Selects Recipharm as Product Characterization Partner	22-11-14	CI
Recipharm AB acquired Arranta Bio Holdings, LLC from Ampersand Capital Partners and others.	22-04-10	CI
Recipharm AB completed the acquisition of Vibalogics GmbH.	22-04-10	CI
Arranta Bio Holdings, LLC agreed to acquire Recipharm AB from Ampersand Capital Partners and others.	22-02-20	CI
Recipharm AB agreed to acquire Vibalogics GmbH.	22-02-17	CI
Recipharm AB acquired GenIBET Biopharmaceuticals, S.A.	22-01-31	CI
Recipharm Secures Vaccine Manufacturing Deal	22-01-27	CI
Recipharm AB agreed to acquire Niche Pharmaceuticals Inc.	22-01-10	CI
Pharmaron Beijing Co., Ltd. acquired Aesica Pharmaceuticals Limited from Recipharm AB.	22-01-09	CI
Transcript : Recipharm AB - Special Call	21-10-27
Recipharm AB Announces First Customer Boards Recipharm's Soft Mist Inhaler Technology Platform	21-09-24	CI
Recipharm Launches New Laboratory to Expand Analytical Services Offering	21-08-24	CI
Recipharm AB Appoints Mr. Manivel Thangapragasam as Associate Director	21-08-24	CI
Recipharm Invests in Fill Finish Capacity	21-07-15	CI
Recipharm : Enters Deal to Operate Fill-Finish Factory in Morocco	21-07-06	MT
Recipharm Signs Memorandum of Understanding for the Fill Finish of Vaccines and Biotherapeutics in Morocco	21-07-06	CI
Moderna, Inc. and Recipharm Site in France Manufacturing Covid-19 Vaccine Moderna Following Approval by European Medicines Agency	21-07-01	CI

Chart Recipharm AB (publ)

Duration

Period

More charts

Company Profile

Recipharm AB (publ) is a Sweden-based pharmaceutical company, operating as a Contract Development and Manufacturing Organization (CDMO). The Company's acivities are devided into four business segments: Advanced Delivery Systems, which develops and manufactures inhalation products and devices including integrated drug solutions, medical check valves and injection devices. Steriles, which manufactures sterile products, including the use of lyophilisation and blow-fillseal (BFS) technologies. Solids & Others, which manufactures non-sterile products, including tablets, capsules, semi-solids, liquids and powders but excluding inhalation products and Development & Licensing, which provides pharmaceutical development services, and manages Recipharm's patents, technologies, and drug product rights, as well as the development and manufacturing of drug substance (Active Pharmaceutical Ingredient, API). The Company operates worldwide.

Sector

Pharmaceuticals

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
INDIVIOR PLC	+18.82%	2.38B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B

Specialty & Advanced Pharmaceuticals